4/15/2004 Twin Falls Chad Baldwin Like many aspiring rodeo cowboys, Kent Cooper began chewing tobacco at a young age -- 13, to be exact. For close to 30 years -- most of those while he was on the pro rodeo circuit -- Copenhagen was his brand of choice, until friends say he dropped the habit four or five years ago. But the lifestyle change came too late for one of Idaho's most successful rodeo cowboys, attorneys for his ex-wife say. The Albion resident, a 13-time qualifier for the National Finals Rodeo in saddle bronc riding, was diagnosed with throat cancer in April 2002 and died later that year in Burley at the age of 47. Now, Cooper's ex-wife, Susan Smith, on behalf of their son, Will, 9, is suing the manufacturer of Copenhagen. The lawsuit contends that the U.S. Smokeless Tobacco Co. and its predecessors "hooked" Cooper on the product, and that they falsely stated for years that chewing tobacco wasn't addictive and there was no proof that it caused harm to people. What's particularly intriguing about the case is the close relationship between the smokeless tobacco industry and the sport of rodeo. The U.S. Smokeless Tobacco Co. is a major sponsor of both the Professional Rodeo Cowboys Association and the National Intercollegiate Rodeo Association, according to their Web sites. Many professional rodeo cowboys have individual sponsorship deals with the company. Some rodeo broncs and bulls are named after chewing tobacco products. Country singer Chris LeDoux, a rodeo icon, even [...]

3/13/2004 Honolulu, HA International Association for Dental Research, Annual Meeting presentation Detailed molecular analysis of tumors is now providing molecular portraits which show the genetic basis of the different clinical presentations of disease. This technology will help identify metastasis signatures and provide logical targets for drug discovery. This moves us closer to a time when we will treat patients based on the genetic profile of the tumor rather than the clinical presentation of the disease. Finding targets that are differentially expressed in cancer and normal tissue will also provide better tests for early diagnosis. There is also increasing interest in utilizing knowledge about tumor biology to address the vexing question as to why tumors recur despite seemingly adequate treatment. A new generation of ultra-sensitive diagnostics has highlighted the problem of subcutaneous foci of residual tumors that may remain at the operative site, or be disseminated throughout the body. These approaches have also revealed that the extent of spread of a precancerous patch is often much greater than previously realized. Long-term follow-up of cases screened by these molecular diagnostics suggests that detecting these troublesome foci of disease can help to identify individuals at risk of developing local and distant recurrence. In a Keynote Address during the 82nd General Session of the International Association for Dental Research, Dr. Maxine Partridge (King's College Hospital, London, UK) reports that a host of novel therapeutic strategies is now on the horizon for management of these problems. These include gene-mediated strategies to replace defective sequences, blocking [...]